Cargando…

MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico

Background. Type 1 Diabetes (T1D) is the most common chronic endocrinological disease diagnosed during childhood. It requires continuous education, monitoring and treatment. An analysis was developed to learn if there were discrepancies in the level of metabolic control and complications between pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Faradji, Raquel N, Garcia Tuomola, Aili L, Antonio Villa, Neftali E, Velazquez, Maricela Vidrio, De la Garza, Natalia E, Capetillo, Mayra Valadez, Bustamante Martinez, Jorge F, Galvez, Guillermo Gonzalez, Ortega, Laura Islas, Sanchez Ruiz, Karla L, Galindo, Carmen Castillo, Polanco Preza, Miguel A, Yepez Rodriguez, Alicia E, Mendez, Angelica Martinez Ramos, Ortiz, Ana Rosa Escobedo, Valenzuela, Julio Cesar, Hermosillo, Aldo Ferreira, Zazueta, Alejandro Romero, Lopez, Sigfrido Miracle, Valdes, Paloma Almeda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208820/
http://dx.doi.org/10.1210/jendso/bvaa046.2248
_version_ 1783530935740792832
author Faradji, Raquel N
Garcia Tuomola, Aili L
Antonio Villa, Neftali E
Velazquez, Maricela Vidrio
De la Garza, Natalia E
Capetillo, Mayra Valadez
Bustamante Martinez, Jorge F
Galvez, Guillermo Gonzalez
Ortega, Laura Islas
Sanchez Ruiz, Karla L
Galindo, Carmen Castillo
Polanco Preza, Miguel A
Yepez Rodriguez, Alicia E
Mendez, Angelica Martinez Ramos
Ortiz, Ana Rosa Escobedo
Valenzuela, Julio Cesar
Hermosillo, Aldo Ferreira
Zazueta, Alejandro Romero
Lopez, Sigfrido Miracle
Valdes, Paloma Almeda
author_facet Faradji, Raquel N
Garcia Tuomola, Aili L
Antonio Villa, Neftali E
Velazquez, Maricela Vidrio
De la Garza, Natalia E
Capetillo, Mayra Valadez
Bustamante Martinez, Jorge F
Galvez, Guillermo Gonzalez
Ortega, Laura Islas
Sanchez Ruiz, Karla L
Galindo, Carmen Castillo
Polanco Preza, Miguel A
Yepez Rodriguez, Alicia E
Mendez, Angelica Martinez Ramos
Ortiz, Ana Rosa Escobedo
Valenzuela, Julio Cesar
Hermosillo, Aldo Ferreira
Zazueta, Alejandro Romero
Lopez, Sigfrido Miracle
Valdes, Paloma Almeda
author_sort Faradji, Raquel N
collection PubMed
description Background. Type 1 Diabetes (T1D) is the most common chronic endocrinological disease diagnosed during childhood. It requires continuous education, monitoring and treatment. An analysis was developed to learn if there were discrepancies in the level of metabolic control and complications between private and public healthcare in Mexico, based on the data obtained in the National Registry of patients with Type 1 Diabetes (RENACED DT1). Objective: Describe the sociodemographic characteristics, metabolic control, treatment and complications in patients receiving private or public health care registered in RENACED DT1.Methodology: Sociodemographic and anthropometric variables, metabolic control, diabetes education, type of insulin and delivery method used for treatment, glucose monitoring and acute and chronic complications were compared between patients receiving private vs public health care. Results Of the 1458 patients registered, significant differences between HbA1c levels were seen (7.8% private health care vs 8.7% public healthcare, p<0.001), achievement of glycemic goal HbA1c <7% (30.1% private healthcare vs 19.6% public healthcare, p<0.001). In private institutions, 47.1% of patients use an insulin pump and 44.7% a basal bolus regimen with insulin analogues (MDI) (p<0.001). Meanwhile in public institutions, 2.6% use an insulin pump and 84.8% use MDI (p<0.001). 30.4% of patients in private institutions check their blood glucose levels 6 to 10 times a day vs 14.3% of patients from public institutions (p<0.001). Continuous glucose monitoring is used in 46.4% of patients from private healthcare vs 5% from public healthcare (p<0.001). A larger number of patients from private healthcare use insulin to carbohydrate ratios to calculate meal insulin compared with patients from public healthcare (89.1% vs 31.3%, p<0.001). No significant differences were found related to the incidence of mild to moderate hypoglycemia, but there was a higher incidence of severe hypoglycemia in the public sector compared to the private one (57 vs 43%, p<0.001). Also, a higher prevalence of diabetic nephropathy was found in patients from public vs private healthcare (82.9 vs 17.1%, p=0.034). Conclusions: Significant differences were found in glucose monitoring, carbohydrate counting and insulin delivery methods, between patients from public and private healthcare, which could explain the differences observed in metabolic control and diabetes associated complications. It is imperative that better public policies are implemented in public health, to reduce this health disparity.
format Online
Article
Text
id pubmed-7208820
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72088202020-05-13 MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico Faradji, Raquel N Garcia Tuomola, Aili L Antonio Villa, Neftali E Velazquez, Maricela Vidrio De la Garza, Natalia E Capetillo, Mayra Valadez Bustamante Martinez, Jorge F Galvez, Guillermo Gonzalez Ortega, Laura Islas Sanchez Ruiz, Karla L Galindo, Carmen Castillo Polanco Preza, Miguel A Yepez Rodriguez, Alicia E Mendez, Angelica Martinez Ramos Ortiz, Ana Rosa Escobedo Valenzuela, Julio Cesar Hermosillo, Aldo Ferreira Zazueta, Alejandro Romero Lopez, Sigfrido Miracle Valdes, Paloma Almeda J Endocr Soc Diabetes Mellitus and Glucose Metabolism Background. Type 1 Diabetes (T1D) is the most common chronic endocrinological disease diagnosed during childhood. It requires continuous education, monitoring and treatment. An analysis was developed to learn if there were discrepancies in the level of metabolic control and complications between private and public healthcare in Mexico, based on the data obtained in the National Registry of patients with Type 1 Diabetes (RENACED DT1). Objective: Describe the sociodemographic characteristics, metabolic control, treatment and complications in patients receiving private or public health care registered in RENACED DT1.Methodology: Sociodemographic and anthropometric variables, metabolic control, diabetes education, type of insulin and delivery method used for treatment, glucose monitoring and acute and chronic complications were compared between patients receiving private vs public health care. Results Of the 1458 patients registered, significant differences between HbA1c levels were seen (7.8% private health care vs 8.7% public healthcare, p<0.001), achievement of glycemic goal HbA1c <7% (30.1% private healthcare vs 19.6% public healthcare, p<0.001). In private institutions, 47.1% of patients use an insulin pump and 44.7% a basal bolus regimen with insulin analogues (MDI) (p<0.001). Meanwhile in public institutions, 2.6% use an insulin pump and 84.8% use MDI (p<0.001). 30.4% of patients in private institutions check their blood glucose levels 6 to 10 times a day vs 14.3% of patients from public institutions (p<0.001). Continuous glucose monitoring is used in 46.4% of patients from private healthcare vs 5% from public healthcare (p<0.001). A larger number of patients from private healthcare use insulin to carbohydrate ratios to calculate meal insulin compared with patients from public healthcare (89.1% vs 31.3%, p<0.001). No significant differences were found related to the incidence of mild to moderate hypoglycemia, but there was a higher incidence of severe hypoglycemia in the public sector compared to the private one (57 vs 43%, p<0.001). Also, a higher prevalence of diabetic nephropathy was found in patients from public vs private healthcare (82.9 vs 17.1%, p=0.034). Conclusions: Significant differences were found in glucose monitoring, carbohydrate counting and insulin delivery methods, between patients from public and private healthcare, which could explain the differences observed in metabolic control and diabetes associated complications. It is imperative that better public policies are implemented in public health, to reduce this health disparity. Oxford University Press 2020-05-08 /pmc/articles/PMC7208820/ http://dx.doi.org/10.1210/jendso/bvaa046.2248 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diabetes Mellitus and Glucose Metabolism
Faradji, Raquel N
Garcia Tuomola, Aili L
Antonio Villa, Neftali E
Velazquez, Maricela Vidrio
De la Garza, Natalia E
Capetillo, Mayra Valadez
Bustamante Martinez, Jorge F
Galvez, Guillermo Gonzalez
Ortega, Laura Islas
Sanchez Ruiz, Karla L
Galindo, Carmen Castillo
Polanco Preza, Miguel A
Yepez Rodriguez, Alicia E
Mendez, Angelica Martinez Ramos
Ortiz, Ana Rosa Escobedo
Valenzuela, Julio Cesar
Hermosillo, Aldo Ferreira
Zazueta, Alejandro Romero
Lopez, Sigfrido Miracle
Valdes, Paloma Almeda
MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
title MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
title_full MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
title_fullStr MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
title_full_unstemmed MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
title_short MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
title_sort mon-lb117 differences in metabolic control, treatment and associated complications in patients living with type 1 diabetes receiving private or public health care in mexico
topic Diabetes Mellitus and Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208820/
http://dx.doi.org/10.1210/jendso/bvaa046.2248
work_keys_str_mv AT faradjiraqueln monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT garciatuomolaailil monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT antoniovillaneftalie monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT velazquezmaricelavidrio monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT delagarzanataliae monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT capetillomayravaladez monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT bustamantemartinezjorgef monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT galvezguillermogonzalez monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT ortegalauraislas monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT sanchezruizkarlal monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT galindocarmencastillo monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT polancoprezamiguela monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT yepezrodriguezaliciae monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT mendezangelicamartinezramos monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT ortizanarosaescobedo monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT valenzuelajuliocesar monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT hermosilloaldoferreira monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT zazuetaalejandroromero monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT lopezsigfridomiracle monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico
AT valdespalomaalmeda monlb117differencesinmetaboliccontroltreatmentandassociatedcomplicationsinpatientslivingwithtype1diabetesreceivingprivateorpublichealthcareinmexico